The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | The expanding role of MRD in CLL
The role of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) is expanding, as discussed here in this insightful interview with Florence Cymbalista, MD, PhD, of Avicenne Hospital, Bobigny, France. Dr Cymbalista adresses the consideration of routine use, as well as the future outlook for MRD in CLL. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
